STOCKS TELEGRAPH

Tag: SLDB

  • Solid Biosciences Inc. (SLDB) stock Yields to Corrections After Hours Following its Huge Gain

    On March 11, Solid Biosciences Inc. (SLDB) plunged under corrections in the after-hours following its huge gain in the regular session. There is no official announcement or SEC filing from the company to explain the recent gains.

    During the regular trading session, SLDB gained a huge 37.38% after fluctuating between $0.7210 and $1.1300. The stock closed the session at a price of $1.0600 per share while 7.04 million shares exchanged hands. Consequently, the stock succumbed to corrections in the after-hours to lose 8.49%. Hence, SLDB was trading at a value of $0.9700 in the after-hours on Friday.

    The Duchenne muscular dystrophy (DMD) treatment’s developer, Solid Biosciences Inc. was founded in 2013. Currently, its 110.3 million outstanding shares trade at a market capitalization of $116.91 million.

    SLDB Stock Movements

    Expanding sanctions and cyberattacks of Russia struck a blow to most of the stocks on March 8. While the classics saw an upsurge including basic material, others witnessed a downfall. The healthcare sector suffered immensely, as a huge number of stocks reached new lows. Among these, SLDB also reported its new low on March 08. Following this, the stock entered a mild uptrend that continued till March 10. On March 11, the stock’s bullish momentum escalated as it increased by a huge 37.38%. Moreover, the 5-day gains of the stock totaled 40.71%, which ultimately called for corrections in the after-hours.

    With no recent news from the company, it seems the stock’s movements are due to external factors including the contribution from the recent low.

    Recent Participations

    Source: BioSpace

    Recently, the company participated in the SVB Leerink 11th Annual Global Healthcare Conference. SLDB’s Chief Operating Officer Joel Schneider and Chief Scientific Officer Carl Morris participated in a fireside chat at the conference on Thursday, February 17, 2022.

    Before this, the company’s CEO, President, and Co-Founder IIan Ganot presented at the 40th Annual J.P. Morgan Healthcare Conference on January 13.

    SLDB’s Financials

    On November 03, the company reported its financial results for the third quarter of 2021.

    In Q3 2021, SLDB had collaboration revenue of $3.5 million while there was none in 2020.

    Moreover, the company incurred a net loss of $18.0 million in Q3 2021, against $21.2 million in the year-ago period.

    Furthermore, the company ended the quarter with cash, cash equivalents, and available-for-sale securities of $229.8 million on September 30, 2021.

  • 31 stocks trending in pre-market

    31 stocks trending in pre-market

    NIO Limited (NIO) stock soared 2.95% to $42.19 in the pre-market trading following the pricing of offering of 68,000,000 American depositary shares. The most recent rating by Goldman, on December 01, 2020, is a Neutral. NIO Inc.

    Veru Inc. (NASDAQ: VERU) shares are trading up 7.17% at $10.39 at the time of writing after declaring positive Phase 2 clinical trial results for enobosarm, for the treatment of endocrine and chemotherapy resistant ER+/HER2- metastatic breast cancer, which was selected as a Spotlight Presentation at the 2020 San Antonio Breast Cancer Symposium. Company’s 52-week ranged between $2.10 to $7.86. Analysts have a consensus price target of $6.

    Occidental Petroleum Corporation (OXY) stock soared 2.45% to $19.64 in the pre-market trading. The most recent rating by MKM Partners, on December 07, 2020, is a Neutral.

    BioCardia Inc. (BCDA), a Biotechnology company, rose about 9.38% at $4.9 in pre-market trading Tuesday after reporting entry into definitive agreements with investors for the purchase and sale of 1,789,474 shares of its common stock at a purchase price of $4.75 per share in a registered direct offering priced at-the-market under Nasdaq rules.

    Genius Brands International Inc. (GNUS) gained over 15.85% at $2.12 in pre-market trading Tuesday December 15, 2020. The company recently revealed that it has secured a commitment to receive $100 million in cash on January 15, 2021 from New York-based Mudrick Capital Management as a result of a new first lien debt financing.

    Nikola Corporation (NKLA) is up more than 2.38% at $16.8 in pre-market hours Tuesday December 15, 2020. The stock had dropped over -6.87% to $16.41 in the last trading session.

    Virgin Galactic Holdings Inc. (SPCE) is up more than 2.83% at $27.22 in pre-market hours Tuesday December 15, 2020 following an update on test flight program. The stock had dropped over -17.38% to $26.47 in the last trading session.

    Before the trading started on December 15, 2020, Huntington Bancshares Incorporated (HBAN) is up 2.32% to reach $12.8 after reporting merger with TCF Financial Corporation to create top 10 U.S. regional bank. It has been trading in a 52-week range of $6.82 to $15.63.

    Plug Power Inc. (PLUG) stock soared 2.65% to $26.38 in the pre-market trading. The most recent rating by B. Riley Securities, on November 10, 2020, is a Buy.

    XPeng Inc. (NYSE: XPEV) shares are trading up 3.86% at $48.99 at the time of writing after its P7 super-long range sports sedan received car of the Year 2021 award in Xuanyuan Awards. Company’s 52-week ranged between $17.11 to $74.49. Analysts have a consensus price target of $58.

    AnPac Bio-Medical Science Co. Ltd. (ANPC), a Biotechnology company, dropped about -5.26% at $5.4 in pre-market trading Tuesday following the proclamation from the firm that it has made significant progress in detecting pre-cancer diseases.

    Yamana Gold Inc. (AUY) stock moved up 2.66 percent to $5.4 in the pre-market trading.

    Zynga Inc. (ZNGA) gained over 3.9% at $9.05 in pre-market trading Tuesday December 15, 2020 following the declaration of pricing of offering of $762 million of convertible senior notes.

    IZEA Worldwide Inc. (IZEA) is down more than -5.68% at $0.9243 in pre-market hours Tuesday December 15, 2020 after announcing that it has seen a surge of new customers in Q4 2020. The stock had jumped over 15.00% to $0.98 in the last trading session.

    Cameco Corporation (CCJ) grew over 3.16% at $13.7 in pre-market trading today.

    Before the trading started on December 15, 2020, HEXO Corp. (HEXO) is down -2.8% to reach $0.9817 after releasing its first quarter fiscal 2021 financial results. It has been trading in a 52-week range of $0.35 to $2.30.

    Nano Dimension Ltd. (NNDM) stock soared 1.8% to $6.77 in the pre-market trading. The most recent rating by Maxim Group, on October 21, 2016, is a Buy.

    Teligent Inc. (TLGT) tumbled over -3.53% at $0.78 in pre-market trading today.

    Synlogic Inc. (NASDAQ: SYBX) shares are trading down -5.51% at $2.4 at the time of writing following advancement of SYNB1891 to combination arm dosing with PD-L1 checkpoint inhibitor in the on-going phase 1 study for the treatment of solid tumors and lymphoma. Company’s 52-week ranged between $1.35 to $3.99.

    BioNTech SE (BNTX) stock soared 5.48% to $114.2 in the pre-market trading. The most recent rating by BofA Securities, on December 01, 2020, is a Neutral. Pfizer Inc. (PFE) and BioNTech SE (BNTX) recently declared additional data on neutralizing antibody and T cell responses from the Phase 1/2 trial with BNT162b2 conducted in Germany

    Torchlight Energy Resources Inc. (TRCH) tumbled over -12.14% at $0.543 in pre-market trading today.

    Seelos Therapeutics Inc. (SEEL) stock moved up 5.47 percent to $1.35 in the pre-market trading after revealing the sale of a $12.0 million senior secured convertible note and shares of Seelos common stock to investors.

    Bed Bath & Beyond Inc. (BBBY) gained over 4.35% at $19.69 in pre-market trading Tuesday December 15, 2020 following the declaration of definitive agreement to sell its remaining non-core banner Cost Plus World Market (CPWM) to Kingswood Capital Management, a Los Angeles-based private equity firm.

    Before the trading started on December 15, 2020, Aerpio Pharmaceuticals Inc. (ARPO) is down -3.33% to reach $1.16. It has been trading in a 52-week range of $0.42 to $2.31.

    Before the trading started on December 15, 2020, Energy Fuels Inc. (UUUU) is up 2.94% to reach $3.15 after reporting that it has entered into a three-year supply agreement with The Chemours Company (CC) to acquire a minimum of 2,500 tons per year of natural monazite sands. It has been trading in a 52-week range of $0.78 to $3.10.

    Uranium Energy Corp. (UEC) grew over 5.62% at $1.69 in pre-market trading today after filing fiscal 2021 Q1 quarterly report.

    MicroVision Inc. (MVIS), a Scientific & Technical Instruments company, rose about 5.43% at $3.3 in pre-market trading Tuesday.

    NovaBay Pharmaceuticals Inc. (NBY) is down more than -2.28% at $0.68 in pre-market hours Tuesday December 15, 2020 after reporting that its proprietary hypochlorous acid solution has received U.S. Environmental Protection Agency (EPA) approval for a kill claim against SARS-CoV-2, the virus that causes COVID-19. The stock had jumped over 0.86% to $0.70 in the last trading session.

    vTv Therapeutics Inc. (VTVT), a Biotechnology company, dropped about -10.44% at $2.66 in pre-market trading Tuesday after declaring a licensing agreement with Anteris Bio for worldwide rights to vTv’s novel clinical-stage Nrf2 activator compound, HPP971.

    Socket Mobile Inc. (NASDAQ: SCKT) shares are trading down -15.38% at $2.42 at the time of writing. Company’s 52-week ranged between $0.76 to $4.50.

    ArcelorMittal (MT) grew over 4.3% at $22.08 in pre-market trading today after announcing investment agreement with Invitalia, an Italian state-owned company.

  • Solid Biosciences (NASDAQ: SLDB) Is Soaring Today. Here’s Why

    Shares of Solid Biosciences Inc. (NASDAQ: SLDB) has traded up 70.44% after the company announced that the US Food and Drug Administration (FDA) gave the permission to resume the IGNITE DMD Phase I/II clinical trial of the company. On July 24, 2020, the company has revealed that it has received the written notice from FDA that its Phase I/II clinical trial of IGNITE DMD will be halted. FDA has requested the information and safety and efficacy data related to the trial.

    Solid Biosciences has provided all the necessary details about the IGNITE DMD Phase I/II clinical trial. The company’s data has fulfilled all the requirements of the FDA and satisfied the drug administration authority. The company has promised to share all the manufacturing details with the FDA and all the changes that remove the majority of empty viral capsids, allowing target dosing to be achieved with fewer viral particles.

    The step of the company to lessen the total amount of virus delivered to each patient is to aid safe dosing of SGT-001 for the duration of the IGNITE DMD trial. In July, the written notification which the company received from FDA has also requested the comparability between SGT-001 made using Solid’s prior manufacturing process and its current, improved process.

    Solid Biosciences has received the FDA acknowledgment by giving the full details of SGT-001 two manufacturing processes. FDA has earlier halted the IGNITE DMD trial after the adverse effects of dosing in the sixth patients in November 2019. Solid Biosciences then gave all the details to the FDA in April 2020.

    In May 2020, the company received the notice of hold on the IGNITE DMD clinical trial. And in July FDA has requested manufacturing information, updated safety, and efficacy data for all patients dosed, and providing direction on total viral load to be injected per patient.

    Solid Biosciences Inc. (NASDAQ: SLDB) shares were trading up70.44% at $3.46 on Thursday. Solid Biosciences Inc. share price went from a low point around $1.93 to briefly over $13.58 in the past 52 weeks, though shares have since pulled back to $3.46. It has moved up 79.27% from its 52-weeks low and moved down -74.52% from its 52-weeks high. SLDB market cap has remained high, hitting $152.66 million at the time of writing.

    SGT-001 of Solid Biosciences is a novel adeno-associated viral (AAV) vector-mediated gene transfer therapy manufactured to treat the underlying genetic cause of Duchenne. Duchenne is caused by mutations in the dystrophin gene that result in the absence or near absence of dystrophin protein.